Evidence map›Paper›PMID 39887941›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Supramolecular Modulation of Tumor Microenvironment Through Host-Guest Recognition and Metal Coordination to Potentiate Cancer Chemoimmunotherapy.

Dan Wu, Jie Zhou, Zhankui Zhang, Yibin Cao, Kunmin Ping, Shaolong Qi, Jianshi Du, Guocan Yu

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Review
  5. Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dan WuCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China.
Jie ZhouCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China.
Zhankui ZhangCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China.
Yibin CaoCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China.
Kunmin PingCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China.
Shaolong QiVascular Surgery Center, The Third Hospital of Jilin University, Changchun, 130031, P. R. China.
Jianshi DuVascular Surgery Center, The Third Hospital of Jilin University, Changchun, 130031, P. R. China.
Guocan YuMinistry of Education Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, P. R. China.ORCID https://orcid.org/0000-0003-1157-4184

Funding

Beijing Municipal Science & Technology Commission Z23110000722300China Postdoctoral Science Foundation 2023M733360National Key R&D Program of China 2023YFC3403102National Key R&D Program of China 2023YFE0204900National Natural Science Foundation of China 22175107National Natural Science Foundation of China 22305140National Natural Science Foundation of China 22305220
6 · The paper itself

Abstract

The massive amount of indoleamine 2,3-dioxygenase 1 (IDO-1) in tumor cells and tumor-associated immune cells forms a feedback loop that maintains immunosuppressive tumor microenvironment (ITM) and causes immune escape, resulting in the poor prognosis of platinum chemotherapeutics. However, the effective systemic administration of platinum drugs and IDO-1 inhibitors is strictly limited by their distinct chemical construction, different pharmacokinetic profiles, and heterogeneous distributions. Herein, a novel supramolecular method with the capability to modulate tumor microenvironment is proposed aiming at potentiating the antitumor efficacy of chemoimmunotherapy. Profiting from the dynamic and reversible merits of noncovalent interactions, IDO-1 inhibitor (IDOi) and 1,2-diaminocyclohexane-platinum(II) (DACHPt) are tailor-encapsulated into supramolecular nanoparticles (SNPs) with the aid of host-guest recognition and metal coordination, respectively, effectively increasing the drug loading and improving their pharmacokinetics. In addition to the authorized chemotherapeutical effect, DACHPt performs a systemic antitumor immune response, which is further magnified by the IDOi-reversed ITM to encourage T lymphocyte infiltration, guaranteeing long-term antitumor immune responses to improve cancer prognosis.

Indexed as

Antineoplastic AgentsImmunotherapyNeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorHumansIndoleamine-Pyrrole 2,3,-DioxygenaseMiceNanoparticlesAntineoplastic AgentsIndoleamine-Pyrrole 2,3,-Dioxygenasecancer theranosticshost‐guest complexnon‐covalent interactionssupramolecular chemistrytumor microenvironment

Identifiers

PMID39887941
PMCPMC11923969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.